Ubs Group Ag Vigil Neuroscience, Inc. Transaction History

Ubs Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.4 - $7.95 $423,222 - $2.4 Million	302,302 Added 182109.64%	302,468 $2.4 Million
Q1 2025 May 13, 2025	BUY	$1.71 - $3.03 $282 - $499	165 Added 16500.0%	166 $0
Q4 2024 Feb 14, 2025	SELL	$1.53 - $4.0 $431 - $1,128	-282 Reduced 99.65%	1 $0
Q3 2024 Nov 14, 2024	SELL	$2.92 - $4.65 $13,213 - $21,041	-4,525 Reduced 94.11%	283 $0
Q2 2024 Aug 13, 2024	SELL	$2.51 - $4.66 $28,470 - $52,858	-11,343 Reduced 70.23%	4,808 $19,000

Q1 2024 May 13, 2024	BUY	$2.68 - $3.63 $43,284 - $58,628	16,151 New	16,151 $55,000
Q1 2023 May 12, 2023	BUY	$8.77 - $12.7 $719 - $1,041	82 Added 16.08%	592 $5,000
Q4 2022 Feb 08, 2023	BUY	$8.74 - $15.99 $4,457 - $8,154	510 New	510 $6,000
Q2 2022 Aug 10, 2022	BUY	$2.23 - $7.81 $3,407 - $11,933	1,528 Added 166.09%	2,448 $6,000
Q1 2022 May 16, 2022	BUY	$7.03 - $17.29 $6,467 - $15,906	920 New	920 $6,000

Ticker VIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,268,600
Market Cap $228M
Description
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.